The goal of the grant process is a serious review of creative new directions in clinical and/or translational research and in need of seed funding. Proposals are invited by our Scientific Advisory Board, rather than accepted as unsolicited requests. The Scientific Advisors generally review proposals in the summer, following invited submissions in May and early June.
There is no set format, but the Foundation generally requests a brief project narrative, lay language summary suitable for public use, annual budget (no more than $240,000 with a maximum of 20% in indirect costs) and budget narrative, with the total not to exceed five pages.
Considerable latitude is given to the investigators in terms of the work proposed. Both the Board of Directors and the Scientific Advisors concur that some of the most important advances in understanding the disease will most likely occur by enabling brilliant minds to pursue some of their most creative theories.
The Foundation's Scientific Advisory Board is comprised of the following breast cancer research leaders:
Larry Norton, MD (Scientific Director), Medical Director of Evelyn H. Lauder Breast Center, Memorial Sloan-Kettering Cancer Center, New York, NY
Clifford Hudis, MD (Chairman), Chief of Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY
Nancy Davidson, MD, Director of the University of Pittsburgh Cancer Institute and Associate Vice Chancellor for Cancer Research of the University of Pittsburgh School of Medicine, Pittsburgh, PA
Patricia A. Ganz, MD, Professor of the Schools of Medicine and Public Health and Director of Cancer Prevention & Control Research, University of California, Los Angeles, CA
Judy E. Garber, MD, MPH, Director of Cancer Risk & Prevention Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Peter Greenwald, MD, Dr.PH, Associate Director for Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD
Gabriel N. Hortobagyi, MD, FACP, Professor of Medicine and Former Chairman of Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
Lajos Pusztai, MD, D.Phil, Professor of Medicine and Co-Director of Yale Cancer Center and Cancer Genetics & Genomics Program, Yale School of Medicine, New Haven, CT
Vered Stearns, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Grants are awarded for a period covering October 1 - September 30, and are paid in two installments in early October and early March. All grantees are required to submit three progress reports; one by January 31, the second by June 15, and a final financial report following the close of the grant year, not later than November 15 . Receipt of the second installment of the year's grant is contingent upon review of the first progress report and a recommendation from the Scientific Advisors.
Grants are generally awarded once a year, for a one-year duration beginning October 1. Pending satisfactory progress and continued need, grants may be renewed for at least a second year.